GCJ904 / Novartis - LARVOL DELTA

CGCJ904A12101: A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors (clinicaltrialsregister.eu) - P1 | N=62 | Not yet recruiting | Sponsor: Novartis Pharma AG | N=27 ➔ 62

Enrollment change • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Kaposi Sarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer

CGCJ904A12101: A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors (clinicaltrialsregister.eu) - P1 | N=27 | Not yet recruiting | Sponsor: Novartis Pharma AG

New P1 trial • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Kaposi Sarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer